CI‐911: A placebo‐controlled study in patients with primary degenerative dementia

Maurice W. Dysken; Susan Anton‐Johnson; Linda Klein; Michael Kuskowski; Lawrence J. Schut; Steven H. Miles; Gabe J. Maletta; Richard De Jong

doi:10.1002/ddr.430120309

CI‐911: A placebo‐controlled study in patients with primary degenerative dementia

Maurice W. Dysken, Susan Anton‐Johnson, Linda Klein, Michael Kuskowski, Lawrence J. Schut, Steven H. Miles, Gabe J. Maletta, Richard De Jong

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Twenty patients with primary degenerative dementia participated in a 6‐week, doseranging, double‐blind, placebo‐controlled study of Cl‐911, a cognition activator that enhances performance in animal models of impaired cognition. Cl‐911 was well tolerated in these patients, but it did not result in significant improvement on objective measures of cognition, social functioning, or self‐care.

Original language	English (US)
Pages (from-to)	267-270
Number of pages	4
Journal	Drug Development Research
Volume	12
Issue number	3-4
DOIs	https://doi.org/10.1002/ddr.430120309
State	Published - 1988

Keywords

Alzheimer's disease
clinical trial
nootropic

Publisher link

10.1002/ddr.430120309

Find It

Find It at U of M Libraries

Cite this

@article{11be9f51525b40be990a887c317f8ca0,

title = "CI‐911: A placebo‐controlled study in patients with primary degenerative dementia",

abstract = "Twenty patients with primary degenerative dementia participated in a 6‐week, doseranging, double‐blind, placebo‐controlled study of Cl‐911, a cognition activator that enhances performance in animal models of impaired cognition. Cl‐911 was well tolerated in these patients, but it did not result in significant improvement on objective measures of cognition, social functioning, or self‐care.",

keywords = "Alzheimer's disease, clinical trial, nootropic",

author = "Dysken, {Maurice W.} and Susan Anton‐Johnson and Linda Klein and Michael Kuskowski and Schut, {Lawrence J.} and Miles, {Steven H.} and Maletta, {Gabe J.} and {De Jong}, Richard",

year = "1988",

doi = "10.1002/ddr.430120309",

language = "English (US)",

volume = "12",

pages = "267--270",

journal = "Drug Development Research",

issn = "0272-4391",

publisher = "John Wiley and Sons Inc.",

number = "3-4",

}

TY - JOUR

T1 - CI‐911

T2 - A placebo‐controlled study in patients with primary degenerative dementia

AU - Dysken, Maurice W.

AU - Anton‐Johnson, Susan

AU - Klein, Linda

AU - Kuskowski, Michael

AU - Schut, Lawrence J.

AU - Miles, Steven H.

AU - Maletta, Gabe J.

AU - De Jong, Richard

PY - 1988

Y1 - 1988

N2 - Twenty patients with primary degenerative dementia participated in a 6‐week, doseranging, double‐blind, placebo‐controlled study of Cl‐911, a cognition activator that enhances performance in animal models of impaired cognition. Cl‐911 was well tolerated in these patients, but it did not result in significant improvement on objective measures of cognition, social functioning, or self‐care.

AB - Twenty patients with primary degenerative dementia participated in a 6‐week, doseranging, double‐blind, placebo‐controlled study of Cl‐911, a cognition activator that enhances performance in animal models of impaired cognition. Cl‐911 was well tolerated in these patients, but it did not result in significant improvement on objective measures of cognition, social functioning, or self‐care.

KW - Alzheimer's disease

KW - clinical trial

KW - nootropic

UR - http://www.scopus.com/inward/record.url?scp=0023917358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023917358&partnerID=8YFLogxK

U2 - 10.1002/ddr.430120309

DO - 10.1002/ddr.430120309

M3 - Article

AN - SCOPUS:0023917358

SN - 0272-4391

VL - 12

SP - 267

EP - 270

JO - Drug Development Research

JF - Drug Development Research

IS - 3-4

ER -

CI‐911: A placebo‐controlled study in patients with primary degenerative dementia

Abstract

Keywords

Publisher link

Find It

Other files and links

Fingerprint

Cite this